Display options
Cite
Vacchelli E, Aranda F, Eggermont A, et al. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology. 2014;3(1):e27048doi: 10.4161/onci.27048.
Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology, 3(1), e27048. https://doi.org/10.4161/onci.27048
Vacchelli, Erika, et al. "Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy." Oncoimmunology vol. 3,1 (2014): e27048. doi: https://doi.org/10.4161/onci.27048
Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology. 2014 Jan 01;3(1):e27048. doi: 10.4161/onci.27048. PMID: 24605265; PMCID: PMC3937194.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2014 Jan 01;3(1):e27048. doi: 10.4161/onci.27048.

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

Oncoimmunology

Erika Vacchelli, Fernando Aranda, Alexander Eggermont, Jérôme Galon, Catherine Sautès-Fridman, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Affiliations

  1. Gustave Roussy; Villejuif, France ; INSERM, U848; Villejuif, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers; Paris, France ; Université Paris-Sud/Paris XI; Paris, France.
  2. Gustave Roussy; Villejuif, France ; INSERM, U848; Villejuif, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers; Paris, France.
  3. Gustave Roussy; Villejuif, France.
  4. Université Paris Descartes/Paris V; Sorbonne Paris Cité; Paris, France ; Université Pierre et Marie Curie/Paris VI; Paris, France ; INSERM, U872; Paris, France ; Equipe 15, Centre de Recherche des Cordeliers; Paris, France.
  5. Université Pierre et Marie Curie/Paris VI; Paris, France ; INSERM, U872; Paris, France ; Equipe 13, Centre de Recherche des Cordeliers; Paris, France.
  6. Gustave Roussy; Villejuif, France ; INSERM, U1015; CICBT507; Villejuif, France.
  7. Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy; Villejuif, France ; INSERM, U848; Villejuif, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers; Paris, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité; Paris, France.
  8. Gustave Roussy; Villejuif, France ; Université Paris Descartes/Paris V; Sorbonne Paris Cité; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers; Paris, France.

PMID: 24605265 PMCID: PMC3937194 DOI: 10.4161/onci.27048

Abstract

In 1997, for the first time in history, a monoclonal antibody (mAb), i.e., the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug Administration for use in cancer patients. Since then, the panel of mAbs that are approved by international regulatory agencies for the treatment of hematopoietic and solid malignancies has not stopped to expand, nowadays encompassing a stunning amount of 15 distinct molecules. This therapeutic armamentarium includes mAbs that target tumor-associated antigens, as well as molecules that interfere with tumor-stroma interactions or exert direct immunostimulatory effects. These three classes of mAbs exert antineoplastic activity via distinct mechanisms, which may or may not involve immune effectors other than the mAbs themselves. In previous issues of

Keywords: bevacizumab; brentuximab vedotin; cetuximab; nimotuzumab; trastuzumab; tumor-associated antigen

References

  1. Oncoimmunology. 2012 Nov 1;1(8):1223-1225 - PubMed
  2. Lancet Oncol. 2006 May;7(5):370 - PubMed
  3. Cancer Immunol Immunother. 2012 Dec;61(12):2367-73 - PubMed
  4. Oncoimmunology. 2013 Jan 1;2(1):e22620 - PubMed
  5. Clin Cancer Res. 2013 Jan 1;19(1):215-24 - PubMed
  6. Lancet Oncol. 2013 Jul;14(8):697-710 - PubMed
  7. Blood. 2012 Dec 6;120(24):4706-11 - PubMed
  8. Clin Cancer Res. 2012 Aug 15;18(16):4415-24 - PubMed
  9. Int J Cancer. 2007 Feb 15;120(4):781-7 - PubMed
  10. Cancer Biol Ther. 2010 Apr 15;9(8):618-31 - PubMed
  11. Clin Cancer Res. 2013 Apr 1;19(7):1784-94 - PubMed
  12. Int J Gynecol Cancer. 2013 Feb;23(2):355-60 - PubMed
  13. Clin Colorectal Cancer. 2006 May;6(1):29-31 - PubMed
  14. J Thorac Dis. 2012 Feb;4(1):58-62 - PubMed
  15. Nat Rev Immunol. 2004 Feb;4(2):153-6 - PubMed
  16. Clin Cancer Res. 2010 Feb 15;16(4):1256-63 - PubMed
  17. Cancer. 2013 Mar 1;119(5):1042-9 - PubMed
  18. Cancer Cell. 2012 Apr 17;21(4):459-72 - PubMed
  19. Haematologica. 2013 Jan;98(1):119-28 - PubMed
  20. Oncoimmunology. 2013 May 1;2(5):e24052 - PubMed
  21. Nature. 1975 Aug 7;256(5517):495-7 - PubMed
  22. Ann Oncol. 2012 Dec;23(12):3104-3110 - PubMed
  23. Clin Cancer Res. 2013 Jul 15;19(14):3914-24 - PubMed
  24. Oncoimmunology. 2012 Dec 1;1(9):1469-1475 - PubMed
  25. J Nucl Med. 2013 Jul;54(7):1014-8 - PubMed
  26. Oncoimmunology. 2012 Jul 1;1(4):493-506 - PubMed
  27. Blood. 1999 Jul 1;94(1):192-8 - PubMed
  28. Clin Cancer Res. 2008 Jan 15;14(2):502-8 - PubMed
  29. Ann Oncol. 2012 Nov;23(11):2820-2827 - PubMed
  30. Nat Rev Immunol. 2009 Oct;9(10):729-40 - PubMed
  31. Invest New Drugs. 2011 Oct;29(5):996-1003 - PubMed
  32. Eur J Cancer. 2013 Apr;49(6):1169-75 - PubMed
  33. Mol Cancer Ther. 2011 Jun;10(6):1072-81 - PubMed
  34. Lancet Oncol. 2013 Mar;14(3):236-43 - PubMed
  35. N Engl J Med. 2004 Jun 3;350(23):2335-42 - PubMed
  36. Hematol Oncol Stem Cell Ther. 2011;4(4):182-4 - PubMed
  37. Invest New Drugs. 2012 Aug;30(4):1585-90 - PubMed
  38. Clin Cancer Res. 2013 Apr 1;19(7):1858-72 - PubMed
  39. Blood. 2009 Jun 4;113(23):5905-10 - PubMed
  40. J Clin Oncol. 2007 Apr 20;25(12):1539-44 - PubMed
  41. J Clin Oncol. 2010 Apr 1;28(10):1749-55 - PubMed
  42. Science. 2012 Sep 28;337(6102):1678-84 - PubMed
  43. Clin Cancer Res. 2013 Feb 15;19(4):920-8 - PubMed
  44. Eur J Cancer. 2013 May;49(8):1799-807 - PubMed
  45. J Cancer. 2011;2:309-16 - PubMed
  46. Am J Clin Oncol. 2012 Oct;35(5):446-50 - PubMed
  47. Ann Oncol. 2010 Feb;21(2):376-381 - PubMed
  48. Clin Cancer Res. 2011 Sep 15;17(18):6052-60 - PubMed
  49. Clin Cancer Res. 2009 Sep 1;15(17):5445-56 - PubMed
  50. Oncoimmunology. 2012 Jan 1;1(1):103-105 - PubMed
  51. Oncology. 2013;85(1):44-52 - PubMed
  52. J Immunother. 2011 Nov-Dec;34(9):611-28 - PubMed
  53. Exp Ther Med. 2012 Jul;4(1):151-157 - PubMed
  54. Am J Clin Oncol. 2013 Feb;36(1):77-82 - PubMed
  55. J Clin Oncol. 2008 Apr 1;26(10):1626-34 - PubMed
  56. Nat Rev Clin Oncol. 2011 Dec 20;9(2):76-8 - PubMed
  57. Lancet. 2014 Jan 4;383(9911):31-39 - PubMed
  58. Lancet Oncol. 2013 Jun;14(7):627-37 - PubMed
  59. Gynecol Oncol. 2013 Jul;130(1):64-8 - PubMed
  60. Cancer Res. 2007 Jul 1;67(13):6253-62 - PubMed
  61. Gynecol Oncol. 2013 Apr;129(1):22-7 - PubMed
  62. Curr Opin Investig Drugs. 2009 Jun;10(6):597-605 - PubMed
  63. Ann Oncol. 2012 Nov;23(11):2812-2820 - PubMed
  64. Br J Cancer. 2013 Jun 25;108(12):2549-56 - PubMed
  65. J Clin Oncol. 2010 Jul 20;28(21):3525-30 - PubMed
  66. Invest New Drugs. 2013 Feb;31(1):85-91 - PubMed
  67. J Clin Oncol. 2012 Oct 1;30(28):3545-51 - PubMed
  68. J Thorac Oncol. 2013 Mar;8(3):338-45 - PubMed
  69. Oncoimmunology. 2013 Nov 1;2(11):e26494 - PubMed
  70. Cancer. 2012 Nov 15;118(22):5497-506 - PubMed
  71. Immunity. 2013 Jul 25;39(1):74-88 - PubMed
  72. Clin Cancer Res. 2012 Oct 15;18(20):5796-805 - PubMed
  73. Lancet Oncol. 2012 Dec;13(12):1234-41 - PubMed
  74. Clin Lung Cancer. 2012 Nov;13(6):505-9 - PubMed
  75. Br J Haematol. 2011 Mar;152(5):579-92 - PubMed
  76. Oncoimmunology. 2013 Mar 1;2(3):e23510 - PubMed
  77. Cell Rep. 2012 Aug 30;2(2):257-69 - PubMed
  78. Oncoimmunology. 2013 Aug 7;2(8):e26084 - PubMed
  79. Gynecol Oncol. 2013 Jun;129(3):452-8 - PubMed
  80. J Clin Oncol. 2009 Feb 10;27(5):672-80 - PubMed
  81. Cancer Discov. 2011 Dec;1(7):562-72 - PubMed
  82. Lancet Oncol. 2013 Feb;14(2):125-33 - PubMed
  83. Br J Cancer. 2013 Aug 20;109(4):934-42 - PubMed
  84. N Engl J Med. 2007 Dec 27;357(26):2666-76 - PubMed
  85. J Clin Oncol. 2013 Feb 10;31(5):573-83 - PubMed
  86. Br J Cancer. 2013 Mar 5;108(4):826-30 - PubMed
  87. Front Biosci (Landmark Ed). 2011 Jan 01;16:277-306 - PubMed
  88. Cancer. 2013 Dec 15;119(24):4290-8 - PubMed
  89. BMC Cancer. 2011 Jan 18;11:21 - PubMed
  90. Oncoimmunology. 2013 Jun 1;2(6):e24677 - PubMed
  91. Gynecol Oncol. 2013 Jun;129(3):459-62 - PubMed
  92. Invest New Drugs. 2012 Dec;30(6):2384-90 - PubMed
  93. Cancer Sci. 2013 Jan;104(1):105-10 - PubMed
  94. Annu Rev Immunol. 2013;31:51-72 - PubMed
  95. Oncoimmunology. 2013 Jan 1;2(1):e22409 - PubMed
  96. Lung Cancer. 2013 Mar;79(3):270-5 - PubMed
  97. Pediatr Blood Cancer. 2013 Sep;60(9):1447-51 - PubMed
  98. Oncoimmunology. 2012 Nov 1;1(8):1445-1447 - PubMed
  99. Expert Opin Investig Drugs. 2009 Jul;18(7):1025-33 - PubMed
  100. Pract Neurol. 2011 Jun;11(3):160-6 - PubMed
  101. Cancer. 2012 Oct 1;118(19):4777-84 - PubMed
  102. Oncoimmunology. 2012 Jul 1;1(4):477-486 - PubMed
  103. Clin Breast Cancer. 2012 Oct;12(5):322-30 - PubMed
  104. Cancer. 2013 Feb 1;119(3):586-92 - PubMed
  105. Eur J Cancer. 2012 Nov;48(17):3140-9 - PubMed
  106. Clin Cancer Res. 2010 Mar 15;16(6):1915-23 - PubMed
  107. Adv Cancer Res. 2009;103:43-73 - PubMed
  108. J Immunother Emphasis Tumor Immunol. 1996 May;19(3):206-17 - PubMed
  109. Invest New Drugs. 2013 Jun;31(3):760-8 - PubMed
  110. Oncoimmunology. 2012 Sep 1;1(6):894-907 - PubMed
  111. Cell Res. 2010 Jan;20(1):34-50 - PubMed
  112. Cancer. 2009 Feb 15;115(4):859-68 - PubMed
  113. Clin Cancer Res. 2011 May 15;17(10):3181-92 - PubMed
  114. J Clin Oncol. 2000 Dec 15;18(24):4077-85 - PubMed
  115. Cancer. 2013 Jan 15;119(2):339-47 - PubMed
  116. Cancer Chemother Pharmacol. 2013 Apr;71(4):1051-7 - PubMed
  117. Lancet Oncol. 2013 May;14(6):461-71 - PubMed
  118. N Engl J Med. 2003 Dec 4;349(23):2184-6 - PubMed
  119. N Engl J Med. 2002 Jan 24;346(4):235-42 - PubMed
  120. Cancer Chemother Pharmacol. 2011 Apr;67(4):837-45 - PubMed
  121. Gynecol Oncol. 2013 Jul;130(1):19-24 - PubMed
  122. Immunity. 2013 Apr 18;38(4):729-41 - PubMed
  123. J Clin Oncol. 2013 Mar 20;31(9):1219-30 - PubMed
  124. Oncoimmunology. 2012 Aug 1;1(5):699-716 - PubMed
  125. Oncotarget. 2013 Jan;4(1):118-27 - PubMed
  126. N Engl J Med. 2011 Dec 29;365(26):2484-96 - PubMed
  127. Ann Oncol. 2013 Feb;24(2):329-336 - PubMed
  128. Lancet Oncol. 2013 Aug;14(9):901-8 - PubMed
  129. Pharm Res. 2007 Oct;24(10):1910-8 - PubMed
  130. Clin Lung Cancer. 2012 Nov;13(6):432-41 - PubMed
  131. Cancer Chemother Pharmacol. 2013 Apr;71(4):1041-50 - PubMed
  132. Oncoimmunology. 2013 May 1;2(5):e24238 - PubMed
  133. Br J Cancer. 2010 Oct 12;103(8):1154-62 - PubMed
  134. J Clin Oncol. 2002 May 15;20(10):2453-63 - PubMed
  135. Cancer. 2012 Oct 15;118(20):5008-14 - PubMed
  136. Gynecol Oncol. 2013 Feb;128(2):221-8 - PubMed
  137. J Thorac Oncol. 2012 Dec;7(12):1823-1829 - PubMed
  138. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6735-42 - PubMed
  139. Clin Cancer Res. 2010 Jun 1;16(11):3044-56 - PubMed
  140. Clin Cancer Res. 2010 Dec 1;16(23):5883-91 - PubMed
  141. Blood. 2012 Jul 19;120(3):560-8 - PubMed
  142. J Clin Oncol. 2013 May 10;31(14):1719-25 - PubMed
  143. Oncoimmunology. 2013 Dec 1;2(12):e26621 - PubMed
  144. Blood. 1999 Aug 15;94(4):1237-47 - PubMed
  145. Cancer Res. 2010 Mar 1;70(5):1793-803 - PubMed
  146. Clin Lymphoma. 2002 Jun;3(1):26-35 - PubMed
  147. J Nucl Med. 2010 Nov;51(11):1780-7 - PubMed
  148. Lancet Oncol. 2012 Jan;13(1):25-32 - PubMed
  149. Cancer Biol Ther. 2012 Jun;13(8):600-5 - PubMed
  150. Zhonghua Zhong Liu Za Zhi. 2011 Aug;33(8):626-8 - PubMed
  151. Oncoimmunology. 2012 Sep 1;1(6):957-958 - PubMed
  152. Cancer Pract. 1998 May-Jun;6(3):195-7 - PubMed
  153. Nat Rev Drug Discov. 2012 Feb 03;11(3):215-33 - PubMed
  154. Oncoimmunology. 2013 Mar 1;2(3):e23402 - PubMed
  155. Eur J Cancer. 2013 Mar;49(5):999-1008 - PubMed
  156. Mol Immunol. 2012 Jun;51(2):227-33 - PubMed
  157. Nat Rev Immunol. 2010 May;10(5):317-27 - PubMed
  158. Ann Oncol. 2013 Jul;24(7):1792-1801 - PubMed
  159. Cancer Invest. 2012 Dec;30(10):727-31 - PubMed
  160. J Clin Oncol. 2012 Nov 20;30(33):4141-7 - PubMed
  161. N Engl J Med. 2012 Jan 12;366(2):109-19 - PubMed
  162. Invest New Drugs. 2012 Jun;30(3):1138-43 - PubMed
  163. Jpn J Clin Oncol. 2013 May;43(5):466-75 - PubMed
  164. Zhonghua Zhong Liu Za Zhi. 2012 Feb;34(2):152-5 - PubMed
  165. Gynecol Oncol. 2012 Dec;127(3):456-61 - PubMed
  166. Lung Cancer. 2011 Jan;71(1):55-9 - PubMed
  167. Blood. 2008 Feb 15;111(4):2170-80 - PubMed
  168. Oncoimmunology. 2012 Jan 1;1(1):75-77 - PubMed
  169. Lancet Oncol. 2013 Mar;14(3):228-35 - PubMed
  170. Ann Oncol. 2012 Nov;23(11):2834-2842 - PubMed
  171. Nat Biotechnol. 2012 Jul 10;30(7):631-7 - PubMed
  172. J Clin Oncol. 2011 Nov 10;29(32):4286-93 - PubMed
  173. N Engl J Med. 2006 Dec 28;355(26):2733-43 - PubMed
  174. Oncoimmunology. 2012 Jan 1;1(1):28-37 - PubMed
  175. Oncoimmunology. 2013 May 1;2(5):e24436 - PubMed
  176. Ann Oncol. 2013 Mar;24(3):784-91 - PubMed
  177. Radiology. 2008 Feb;246(2):497-507 - PubMed
  178. Ann Oncol. 2013 Jan;24(1):145-52 - PubMed
  179. Ann Oncol. 2013 Mar;24(3):702-9 - PubMed
  180. Pharmacol Ther. 2012 Dec;136(3):334-42 - PubMed
  181. Oncoimmunology. 2013 Jul 1;2(7):e24964 - PubMed
  182. EMBO Mol Med. 2013 Aug;5(8):1213-26 - PubMed
  183. Clin Cancer Res. 2013 Dec 1;19(23):6614-23 - PubMed
  184. Immunity. 2006 Jan;24(1):19-28 - PubMed
  185. Oncoimmunology. 2013 Jul 1;2(7):e24850 - PubMed
  186. Clin Cancer Res. 2013 Jan 1;19(1):236-46 - PubMed
  187. Ann Oncol. 2013 Jan;24(1):257-63 - PubMed
  188. Anticancer Res. 2012 Dec;32(12):5501-6 - PubMed
  189. Br J Cancer. 2009 Jan 27;100(2):366-9 - PubMed
  190. Nat Rev Drug Discov. 2012 Jan 03;11(1):19-20 - PubMed
  191. Oncoimmunology. 2012 Oct 1;1(7):1197-1199 - PubMed
  192. N Engl J Med. 2010 Sep 30;363(14):1324-34 - PubMed
  193. N Engl J Med. 2007 May 31;356(22):2271-81 - PubMed
  194. Oncoimmunology. 2013 Jan 1;2(1):e22789 - PubMed
  195. J Clin Oncol. 2011 Jun 20;29(18):2493-8 - PubMed
  196. Mol Med. 2013 May 20;19:99-108 - PubMed
  197. Clin Cancer Res. 2008 Mar 1;14(5):1296-302 - PubMed
  198. N Engl J Med. 2012 Nov 8;367(19):1783-91 - PubMed
  199. Cancer Chemother Pharmacol. 2013 Jan;71(1):227-35 - PubMed
  200. Leuk Lymphoma. 2009 Aug;50(8):1336-44 - PubMed
  201. Cancer Sci. 2012 Nov;103(11):1979-84 - PubMed
  202. Blood. 2012 Dec 20;120(26):5185-7 - PubMed
  203. Cancer Lett. 2007 Jun 18;251(1):146-57 - PubMed
  204. J Clin Oncol. 1998 Aug;16(8):2825-33 - PubMed
  205. Ann Oncol. 2013 Jan;24(1):220-5 - PubMed
  206. J Clin Oncol. 2013 Jul 10;31(20):2586-92 - PubMed
  207. Mol Cancer Ther. 2009 May;8(5):1095-105 - PubMed
  208. Oncoimmunology. 2013 Sep 1;2(9):e25595 - PubMed
  209. Am J Clin Oncol. 2013 Jun;36(3):254-7 - PubMed
  210. J Thorac Oncol. 2013 Mar;8(3):329-37 - PubMed
  211. J Clin Oncol. 2013 Feb 20;31(6):724-30 - PubMed
  212. Lancet Oncol. 2013 Jan;14(1):29-37 - PubMed
  213. Clin Cancer Res. 2010 Jan 15;16(2):699-710 - PubMed
  214. Lancet Oncol. 2013 May;14(6):490-9 - PubMed
  215. Blood. 2000 Aug 15;96(4):1259-66 - PubMed
  216. Oncoimmunology. 2013 Mar 1;2(3):e24567 - PubMed
  217. Ann Hematol. 2002 Jan;81(1):26-32 - PubMed
  218. Lancet Oncol. 2013 May;14(6):481-9 - PubMed
  219. Exp Cell Res. 2011 May 15;317(9):1255-60 - PubMed
  220. J Cancer Res Clin Oncol. 2013 Mar;139(3):447-55 - PubMed
  221. Oncogene. 2012 Apr 12;31(15):1869-83 - PubMed
  222. Oncoimmunology. 2013 Aug 1;2(8):e25238 - PubMed
  223. Cancer Chemother Pharmacol. 2013 Apr;71(4):955-63 - PubMed
  224. Cancer Chemother Pharmacol. 2011 Sep;68(3):733-41 - PubMed
  225. Oncogene. 2007 May 28;26(25):3745-57 - PubMed
  226. Zhonghua Zhong Liu Za Zhi. 2011 Mar;33(3):232-5 - PubMed
  227. Curr Opin Mol Ther. 2010 Aug;12(4):487-95 - PubMed
  228. Clin Cancer Res. 2012 Nov 1;18(21):6049-57 - PubMed
  229. J Clin Oncol. 2011 Apr 1;29(10):1252-60 - PubMed
  230. Nat Rev Drug Discov. 2004 May;3(5):391-400 - PubMed
  231. Blood. 2013 Jan 17;121(3):476-84 - PubMed
  232. Nat Rev Clin Oncol. 2011 Mar;8(3):151-60 - PubMed
  233. Cancer Chemother Pharmacol. 2013 Jun;71(6):1473-83 - PubMed
  234. MAbs. 2010 Jul-Aug;2(4):440-8 - PubMed
  235. Br J Cancer. 2013 Mar 19;108(5):1052-60 - PubMed
  236. Oncoimmunology. 2013 Apr 1;2(4):e23803 - PubMed
  237. Int J Oncol. 2006 Feb;28(2):421-30 - PubMed
  238. Blood. 2012 Jun 28;119(26):6226-33 - PubMed
  239. Ann Oncol. 2013 Jan;24(1):90-6 - PubMed
  240. Oncoimmunology. 2012 Sep 1;1(6):810-821 - PubMed
  241. J Clin Oncol. 2012 May 10;30(14):1594-600 - PubMed
  242. Int J Gynecol Cancer. 2013 Jan;23(1):73-80 - PubMed
  243. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012 Jul;47(7):536-9 - PubMed
  244. Clin Cancer Res. 2011 Jun 15;17(12):4091-100 - PubMed
  245. Lancet Oncol. 2013 Apr;14(4):371-82 - PubMed
  246. J Clin Oncol. 2009 Jul 20;27(21):3557-65 - PubMed
  247. Clin Cancer Res. 2012 Oct 15;18(20):5752-60 - PubMed
  248. Oncoimmunology. 2012 Mar 1;1(2):179-188 - PubMed
  249. Cancer Res. 1999 Jan 15;59(2):347-52 - PubMed

Publication Types